生物
血管生成
癌症研究
转移
趋化因子
三阴性乳腺癌
免疫学
肿瘤微环境
癌细胞
乳腺癌
癌症
细胞因子
免疫系统
遗传学
作者
Eun Sook Kim,Su Min Nam,Hye Kyung Song,Seung‐Eun Lee,Kyoungmee Kim,Hyun Lim,Hyun‐Sook Lee,Kyu Tae Kang,Yeo Jung Kwon,Young Jin Chun,So Yeon Park,Joohee Jung,Aree Moon
出处
期刊:Oncogene
[Springer Nature]
日期:2021-04-08
卷期号:40 (18): 3245-3259
被引量:13
标识
DOI:10.1038/s41388-021-01758-w
摘要
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a poor prognosis for which no effective therapeutic measures are currently available. The present study aimed to investigate whether interactions with endothelial colony-forming cells (ECFCs) promote aggressive progression of TNBC cells. Herein, using an indirect co-culture system, we showed that co-culture increased the invasive and migratory phenotypes of both MDA-MB-231 TNBC cells and ECFCs. Through a cytokine antibody array and RT-PCR analysis, we revealed that co-culture markedly induced secretion of the chemokine C-C motif ligand (CCL)8 from ECFCs and that of interleukin (IL)-8 from MDA-MB-231 cells. CCL8 was crucial for ECFC-induced IL-8 secretion and invasion of MDA-MB-231 cells as well as for MDA-MB-231-enhanced MMP-2 secretion and angiogenesis of ECFCs. We suggest c-Jun as a transcription factor for CCL8-induced IL-8 expression in MDA-MB-231 cells. IL-8 was important for co-culture-induced CCL8 and MMP-2 upregulation and invasion of ECFCs. Notably, our findings reveal a positive feedback loop between CCL8 and IL-8, which contributes to the aggressive phenotypes of both ECFC and TNBC cells. Using an MDA-MB-231 cell-based xenograft model, we show that tumor growth and metastasis are increased by co-injected ECFCs in vivo. Increased expression of IL-8 was observed in tissues with bone metastases in mice injected with conditioned media from co-cultured cells. High IL-8 levels are correlated with poor recurrence-free survival in TNBC patients. Together, these results suggest that CCL8 and IL-8 mediate the crosstalk between ECFCs and TNBC, leading to aggravation of tumorigenicity in TNBC.
科研通智能强力驱动
Strongly Powered by AbleSci AI